Results 51 to 60 of about 21,329 (69)

Publisher Correction: Pre-conceptional paternal diet impacts on offspring testosterone homoeostasis via epigenetic modulation of cyp19a1/aromatase activity

npj Metabolic Health and Disease
Arianna Pastore, Nadia Badolati, Francesco Manfrevola, Serena Sagliocchi, Valentina Laurenzi, Giorgia Musto, Veronica Porreca, Melania Murolo, Teresa Chioccarelli, Roberto Ciampaglia, Valentina Vellecco, Mariarosaria Bucci, Monica Dentice, Gilda Cobellis, Mariano Stornaiuolo   +14 more
doaj   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Loss of immunity-related GTPase GM4951 leads to nonalcoholic fatty liver disease without obesity

Nature Communications, 2022
Zhao Zhang, Jeffrey A Sorelle, Eva Marie Y Moresco   +2 more
exaly  

JTZ-951 (enarodustat), a hypoxia-inducible factor prolyl hydroxylase inhibitor, improves iron utilization and anemia of inflammation: Comparative study against recombinant erythropoietin in rat

European Journal of Pharmacology, 2021
Yuichi Shinozaki
exaly  

KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples

Translational Lung Cancer Research, 2020
Nan Du, Mingjiang Li, Ming Yao
exaly  

JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor

European Journal of Pharmacology, 2019
Yuichi Shinozaki, Tetsuhiro Tanaka, Masaomi Nangaku   +2 more
exaly  

Effects of SK-951, a Benzofuran Derivative, as a Prokinetic Agent in Rats and Dogs.

The Japanese Journal of Pharmacology, 1999
Katsura Tsukamoto
exaly   +2 more sources

Galileo Encounter with 951 Gaspra: First Pictures of an Asteroid

Science, 1992
Paul Helfenstein, Clark R Chapman, James W Head   +2 more
exaly  

Discovery of JTZ-951: A HIF Prolyl Hydroxylase Inhibitor for the Treatment of Renal Anemia

ACS Medicinal Chemistry Letters, 2017
Yosuke Ogoshi
exaly  

Hemodialysis Clearance of Enarodustat (JTZ‐951), an Oral Erythropoiesis Stimulating Agent, in Patients with End‐Stage Renal Disease

Clinical Pharmacology in Drug Development, 2021
exaly  

Leishmaniasis

Lancet, The, 2019
Suman Saurabh
exaly